Glenmark Of India Seeks Government Probe Into Trial Manipulator
This article was originally published in PharmAsia News
India's Glenmark Pharmaceuticals accused a government hospital participating in a trial of one of its drug trials of manipulating data and engaging in unfair practices, causing a halt of the trial. Glenmark filed a complaint with the Drug Controller General of India asking for an immediate audit of the hospital. At issue is Glenmark's Oglemilast asthma drug based on a PDE4 inhibitor molecule. The complaint also questioned whether the screening of volunteers was done properly. (Click here for more
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.